DISCLAIMERS

The information provided here is general reimbursement information for LUMASON. It is not legal advice, nor is it advice about how to code, complete, or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider’s responsibility to determine and submit appropriate codes, charges, modifiers, and bills for the services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.

CPT® copyright 2019 American Medical Association (AMA). All rights reserved. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

Committed to Science, Committed to You.™
CONTENTS

LUMASON Ultrasound Enhancing Agent Indications ................................................................. 3
Coding Nomenclature ............................................................................................................. 4
Coding Information ............................................................................................................... 5-6
Pass-Through Payment ........................................................................................................... 7
Example of Billing ................................................................................................................... 8
Medicare National Average Payment Rates ........................................................................... 9-11
Hospital In-Patient Billing and Coverage ............................................................................. 12
Ordering Information .............................................................................................................. 13
Reimbursement Hotline .......................................................................................................... 14
References ............................................................................................................................... 15
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

INDICATIONS AND USAGE

LUMASON® is an ultrasound contrast agent indicated for use:

• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms

• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients

• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON® is contraindicated in patients with:

• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].

• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.
CPT® (Current Procedural Terminology)
Codes used to report the service or procedure performed.

HCPCS (Healthcare Common Procedure Coding System)
Codes used to report the provision of supplies, materials, injections, and certain services and procedures. For example, the HCPCS code for LUMASON ultrasound enhancing agent is Q9950.

C-codes
Unique, temporary HCPCS codes created by Medicare and used for HOPPS only. This is often done when no other appropriate code exists. An example of this is the C-code series in echocardiography, which are described on page 9.

ICD-10 (International Classification of Disease)
Codes used to describe a patient’s signs and symptoms that would represent a medically necessary reason for performing the procedure. ICD-10 codes need to be entered on the claim form. ICD-10 is the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization (WHO).

APC (Ambulatory Payment Classification)
In most cases, the unit of payment under the HOPPS is the APC. CMS assigns individual services HCPCS & CPT codes to APCs based on similar clinical characteristics and similar costs. The payment rate and copayment calculated for an APC apply to each service within the APC. In 2019 CMS did not make changes to the APC structure from 2018.

NDC (National Drug Code)
An NDC code provides a unique identifier for a specific drug. The NDC for LUMASON ultrasound enhancing agent is: 0270-7099-16.

Medicare Addendum B
These files are updated quarterly and reflect hospital HOPPS payment rates for HCPCS codes and APC codes. This is also where the Pass-Through code for LUMASON (Q9950) can be found: www.cms.gov/Medicare/Medicare-Fee-For-Service-Payment/HospitalOutpatientpps/Addendum-A-and-Addendum-B-Updates.html.

Medicare Part B ASP (average selling price) file
Quarterly payment files are published for Independent Diagnostic Testing Facilities (IDTFs) and physician offices. This is where the payment value for LUMASON (Q9950) can be found: www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html.

Medicare Physician Fee Schedule (MPFS)
Find out physician payment for specific geographic locations in the country for different procedures. This schedule provides: global (G), technical (TC), and professional (26) component payment rates. See MEDICARE NATIONAL AVERAGE PAYMENTS FOR PHYSICIAN OFFICE/IDTFs chart for echocardiography and ultrasound procedures covered on page 12 of this guide. To find out more information on specific locations visit: www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSLookup/index.html?redirect=/pfslookup.
CODING INFORMATION

Q9950*: LUMASON ultrasound enhancing agent
1 vial = 5 mL
Billing unit is per mL
*Pass through payment available through September 30, 2020

Medicare Patients: LUMASON ultrasound enhancing agent is separately payable because of its Pass-Through payment status. Code separately with the echocardiography and radiology procedure codes.

Use of JW Modifier: CMS requires the use of the JW modifier to indicate the number of mL or units discarded for single-use vial drugs that are paid separately. See examples on page 8.

Commercially insured patients: The provider must contact their respective insurance providers to include Q9950 and establish a reimbursement value.

Procedure Codes: Echocardiography: 933xx series and C-8921-30 code series. Please see page 10 for a complete list.

Please note that C-codes series is for HOPPS only and generally for Medicare patients.

New Add-On Code:

+93356 Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

INDICATIONS AND USAGE

LUMASON® is an ultrasound contrast agent indicated for use:
• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON® is contraindicated in patients with:
• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of Lumason [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.
Ultrasonography of the liver

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>76978</td>
<td>Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion</td>
</tr>
<tr>
<td>+76979, add-on code</td>
<td>Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)</td>
</tr>
</tbody>
</table>

Alternate Coding from the American Medical Association

Ultrasonography of the urinary tract for vesicoureteral reflux

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>51600</td>
<td>Injection procedure for cystography or voiding urethrocystography</td>
</tr>
<tr>
<td>74455</td>
<td>Urethrocystography, voiding, radiological supervision and interpretation</td>
</tr>
<tr>
<td>74430</td>
<td>Cystography, minimum of 3 views, radiological supervision and interpretation</td>
</tr>
</tbody>
</table>

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

INDICATIONS AND USAGE

LUMASON® is an ultrasound contrast agent indicated for use:
- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON® is contraindicated in patients with:
- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of Lumason [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.

Committed to Science, Committed to You.™
What is Pass-Through Payment?
In accordance with Public Law 115-141, LUMASON ultrasound enhancing agent is receiving Pass-Through Payment Status for 2 years effective October 1, 2018 until September 30, 2020.

Payment in an outpatient hospital clinic is based on a prospective payment system (HOPPS). The system is based on groups of procedures, medical visits, and ancillary services. Under the HOPPS system, enhancing agents are not separately payable; rather they are packaged or bundled with the procedure.

• A Pass-Through payment is a temporary additional payment for Hospital Outpatient facilities for innovative devices, drugs, and biologicals for Medicare beneficiaries. It is not subject to coinsurance of packaging rules.
• LUMASON ultrasound enhancing agent qualifies for this additional Pass-Through payment through September 30, 2020.
• There is no need to enter a specific code for the Pass-Through status. The HCPCS code Q9950 works as the Pass-Through code.
• As of January 1, 2020, the value of this payment is $19.535 per mL and equivalent to $97.68/vial.
• Stay up to date by visiting the Medicare Addendum B website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalOutpatientPPS/Addendum-A-and-Addendum-BUpdates.html
• It is important to remember to code Q9950 and the amount discarded for a total of 5mL per vial to benefit from the Pass-Through payment along with the specific Procedure performed. A JW modifier represents the amount discarded.

LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

INDICATIONS AND USAGE
LUMASON® is an ultrasound contrast agent indicated for use:
• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS
LUMASON® is contraindicated in patients with:
• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].
• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of Lumason [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.html or call 1-800-FDA-1088.
Sample hospital setting billing form UB-04 CMS-1450

Echocardiography with contrast

<table>
<thead>
<tr>
<th>Form Locator 42 (Rev. CD)</th>
<th>Enter Revenue Code:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0254 Drugs incident to diagnostic service</td>
<td></td>
</tr>
<tr>
<td>0636 Drugs requiring detailed coding</td>
<td></td>
</tr>
<tr>
<td>(Verify Revenue Code with Hospital Billing Department and Insurance Providers)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Form Locator 44 (HCPCS/Rates/HIPPS Code)</th>
<th>Enter CPT® or HCPCS code for procedure and radiopharmaceutical</th>
</tr>
</thead>
<tbody>
<tr>
<td>C8929 Echocardiography</td>
<td>Q9950 LUMASON® (Retains Pass-Through status until Sept. 2020)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Form Locator 46 (Units of Service)</th>
<th>Enter number of units based on the HCPCS descriptor</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**JW Modifier**

Applied to the amount of contrast drug that is discarded

**Bracco Diagnostics Inc. cannot guarantee coverage or payment for products or procedures at any particular level. For more specific information please contact your Medicare contractor or the patient’s insurer.**
Echocardiography: C-codes

<table>
<thead>
<tr>
<th>HCPCS code</th>
<th>Long-description HCPCS</th>
<th>2020 HOPPS National Payment Rate - HCPCS3</th>
</tr>
</thead>
<tbody>
<tr>
<td>C8921</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; complete</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8922</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; follow-up or limited study</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8923</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8924</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study</td>
<td>$381.81</td>
</tr>
<tr>
<td>C8925</td>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, real time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8926</td>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8927</td>
<td>Transesophageal echocardiography (TEE) with contrast, or without contrast followed by with contrast, for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8928</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8929</td>
<td>Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography</td>
<td>$680.74</td>
</tr>
<tr>
<td>C8930</td>
<td>Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision</td>
<td>$680.74</td>
</tr>
</tbody>
</table>

Echocardiography: Cross Walk Codes Without and With Contrast

<table>
<thead>
<tr>
<th>CPT</th>
<th>without contrast</th>
<th>with contrast</th>
<th>C-code</th>
</tr>
</thead>
<tbody>
<tr>
<td>93303</td>
<td></td>
<td></td>
<td>C8921</td>
</tr>
<tr>
<td>93304</td>
<td></td>
<td></td>
<td>C8922</td>
</tr>
<tr>
<td>93306</td>
<td></td>
<td></td>
<td>C8929</td>
</tr>
<tr>
<td>93307</td>
<td></td>
<td></td>
<td>C8923</td>
</tr>
<tr>
<td>93308</td>
<td></td>
<td></td>
<td>C8924</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CPT</th>
<th>without contrast</th>
<th>with contrast</th>
<th>C-code</th>
</tr>
</thead>
<tbody>
<tr>
<td>93312</td>
<td></td>
<td></td>
<td>C8925</td>
</tr>
<tr>
<td>93315</td>
<td></td>
<td></td>
<td>C8926</td>
</tr>
<tr>
<td>93318</td>
<td></td>
<td></td>
<td>C8927</td>
</tr>
<tr>
<td>93350</td>
<td></td>
<td></td>
<td>C8928</td>
</tr>
<tr>
<td>93351</td>
<td></td>
<td></td>
<td>C8930</td>
</tr>
</tbody>
</table>
### Echocardiography CPT® codes for adult and pediatric patients

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Long-description CPT®</th>
<th>2020 HOPPS National Payment Rate - CPT®</th>
</tr>
</thead>
<tbody>
<tr>
<td>93303</td>
<td>Transthoracic echocardiography for congenital cardiac anomalies; complete</td>
<td>$481.53</td>
</tr>
<tr>
<td>93304</td>
<td>Transthoracic echocardiography for congenital cardiac anomalies; follow-up or limited study</td>
<td>$481.53</td>
</tr>
<tr>
<td>93306</td>
<td>Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography</td>
<td>$481.53</td>
</tr>
<tr>
<td>93307</td>
<td>Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, complete, without spectral or color doppler echocardiography</td>
<td>$233.01</td>
</tr>
<tr>
<td>93308</td>
<td>Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, follow-up or limited study</td>
<td>$233.01</td>
</tr>
<tr>
<td>93312</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); including probe placement, image acquisition, interpretation and report</td>
<td>$481.53</td>
</tr>
<tr>
<td>93313</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); placement of transesophageal probe only</td>
<td>$481.53</td>
</tr>
<tr>
<td>93314</td>
<td>Echocardiography, transesophageal, real-time with image documentation (2d) (with or without m-mode recording); image acquisition, interpretation and report only</td>
<td>packaged</td>
</tr>
<tr>
<td>93315</td>
<td>Transesophageal echocardiography for congenital cardiac anomalies; including probe placement, image acquisition, interpretation and report</td>
<td>$481.53</td>
</tr>
<tr>
<td>93316</td>
<td>Transesophageal echocardiography for congenital cardiac anomalies; placement of transesophageal probe only</td>
<td>$481.53</td>
</tr>
<tr>
<td>93317</td>
<td>Transesophageal echocardiography for congenital cardiac anomalies; image acquisition, interpretation and report only</td>
<td>packaged</td>
</tr>
<tr>
<td>93318</td>
<td>Echocardiography, transesophageal (TEE) for monitoring purposes, including probe placement, real time 2-dimensional image acquisition and interpretation leading to ongoing (continuous) assessment of (dynamically changing) cardiac pumping function and to therapeutic measures on an immediate time basis</td>
<td>$481.53</td>
</tr>
<tr>
<td>93350</td>
<td>Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report</td>
<td>$481.53</td>
</tr>
<tr>
<td>93351</td>
<td>Echocardiography, transthoracic, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with supervision by a physician or other qualified health care professional</td>
<td>$481.53</td>
</tr>
<tr>
<td>93352</td>
<td>Use of echocardiographic enhancing agent during stress echocardiography (list separately in addition to code for primary procedure)</td>
<td>not paid under OPPS</td>
</tr>
<tr>
<td>93355</td>
<td>Echocardiography, transesophageal (TEE) for guidance of a transcatheter intracardiac or great vessel(s) structural intervention(s) (eg, tavr, transcathether pulmonary valve replacement, mitral valve repair, paravalvar regurgitation repair, left atrial appendage occlusion/closure, ventricular septal defect closure) (peri-and intra-procedural), real-time image acquisition and documentation, guidance with quantitative measurements, probe manipulation, interpretation, and report, including diagnostic transesophageal echocardiography and, when performed, administration of ultrasound contrast, doppler, color flow; and 3d</td>
<td>packaged</td>
</tr>
<tr>
<td>93320</td>
<td>Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (list separately in addition to codes for echocardiographic imaging); complete</td>
<td>packaged</td>
</tr>
<tr>
<td></td>
<td>Add-on code, use 93320 in conjunction with 93303, 93304, 93312, 93314, 93315, 93317, 93350, 93351, C8921, C8922, C8925, C8926, C8928, C8930</td>
<td>packaged</td>
</tr>
<tr>
<td>93321</td>
<td>Doppler echocardiography, pulsed wave and/or continuous wave with spectral display (list separately in addition to codes for echocardiographic imaging); follow-up or limited study (list separately in addition to codes for echocardiographic imaging)</td>
<td>packaged</td>
</tr>
<tr>
<td></td>
<td>Add-on code, use 93321 in conjunction with 93303, 93304, 93308, 93312, 93314, 93315, 93317, 93350, 93351, C8921, C8922, C8924, C8925, C8926, C8928, C8930</td>
<td>packaged</td>
</tr>
<tr>
<td>93325</td>
<td>Doppler echocardiography color flow velocity mapping (list separately in addition to codes for echocardiography)</td>
<td>packaged</td>
</tr>
<tr>
<td></td>
<td>Add-on code, use 93325 in conjunction with 76825, 76826, 76827, 76828, 93303, 93304, 93308, 93312, 93314, 93315, 93317, 93350, 93351, C8921, C8922, C8924, C8925, C8926, C8928, C8930</td>
<td>packaged</td>
</tr>
</tbody>
</table>

**New as of January 1, 2020**

| +93356 | Myocardial strain imaging using speckle tracking derived assessment of myocardial mechanics. | packaged |
**Radiology - Liver and Urinary Tract**

### Ultrasonography of the liver and urinary tract for vesicoureteral reflux

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Description</th>
<th>2020 HOPPS National Payment Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>76978</td>
<td>Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); initial lesion</td>
<td>$182.20</td>
</tr>
<tr>
<td>+76979, add-on code</td>
<td>Ultrasound, targeted dynamic microbubble sonographic contrast characterization (non-cardiac); each additional lesion with separate injection (List separately in addition to code for primary procedure)</td>
<td>Packaged</td>
</tr>
</tbody>
</table>

**Alternate Coding from the American Medical Association**

### Ultrasonography of the urinary tract for vesicoureteral reflux

<table>
<thead>
<tr>
<th>CPT® code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>51600</td>
<td>Injection procedure for cystography or voiding urethrocystography</td>
</tr>
<tr>
<td>74455</td>
<td>Urethrocystography, voiding, radiological supervision and interpretation</td>
</tr>
<tr>
<td>74430</td>
<td>Cystography, minimum of 3 views, radiological supervision and interpretation</td>
</tr>
</tbody>
</table>

**Note: LUMASON must be coded separately**

**LUMASON ultrasound enhancing agent**

<table>
<thead>
<tr>
<th>HCPCS code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q9950</td>
<td>Sulfur hexafluoride lipid microspheres, per mL; there are 5 mL per single-use vial of LUMASON. LUMASON is paid separately in HOPPS for Medicare patient due to its Pass-Through payment status - see page 7 for more details</td>
</tr>
</tbody>
</table>

**LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use**

**INDICATIONS AND USAGE**

LUMASON® is an ultrasound contrast agent indicated for use:

- in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
- in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
- in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

**CONTRAINDICATIONS**

LUMASON® is contraindicated in patients with:

- history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

**IMPORTANT SAFETY INFORMATION**

**WARNING: SERIOUS CARDIOPULMONARY REACTIONS**

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

- Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
- Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of Luminason [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.html or call 1-800-FDA-1088.
Hospital in-patient billing: Medicare Severity Adjusted Diagnosis Related Groups (MS-DRG)

ICD-10 procedure codes are used for in-patient billing. They indicate the surgical and/or diagnostic procedures performed on the patient. These codes, in combination with diagnosis codes, help determine the assignment to an MS-DRG payment category under Medicare and other payment systems. Payment in the hospital is determined by the MS-DRG. Under this system, a hospital is paid at a predetermined specific rate for each Medicare discharge. Fixed reimbursement is established for hospital services based on the patient diagnosis and is paid regardless of the actual cost the hospital incurs in providing the services. Ultrasound exams and contrast agents are part of the MS-DRG payment.

Coverage: Medicare National Coverage Decisions (NCD)

Echocardiography is included in the Medicare NCD for ultrasound and is limited. There are Medicare Local Coverage Decisions (LCDs) for echocardiography with contrast.

The echocardiography LCDs can be found on the CMS website at:

The Medicare National Coverage Determination (NCD) for ultrasound is non-specific. Abdominal and retroperitoneal ultrasound are covered if medically appropriate.

Medicare National Coverage Determinations Manual, Chapter 1, Part 4, Section 220.5
LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use

INDICATIONS AND USAGE

LUMASON® is an ultrasound contrast agent indicated for use:

• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON® is contraindicated in patients with:

• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of Lumason [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.htm or call 1-800-FDA-1088.


LUMASON ORDERING INFORMATION

Ordering information

<table>
<thead>
<tr>
<th>NDC#</th>
<th>0270-7099-16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product description</td>
<td>LUMASON (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, 25 mg/vial</td>
</tr>
<tr>
<td>Packaging</td>
<td>5 kits per box</td>
</tr>
</tbody>
</table>
How we support you
The Bracco Reimbursement Hotline is here to support you for all your reimbursement needs.
Ask coding and billing questions regarding Bracco Diagnostics products and procedures related to those products.

- HCPCS codes for products
- CPT® and HCPCS codes for procedures
- Medicare payments
- Monday-Friday: 9:00 AM-6:00 PM Eastern Time

For more information on reimbursement, contact the Bracco Reimbursement Hotline at:

1-800-349-1388
Askbracco@reimbursement.bracco.com

Receive Bi-monthly Reimbursement/Compliance Question & Answers

Access a Q&A Searchable Database:
- Search by topics and gain access to the archived Q&A
- Reach the hotline from the webpage
- Organized by Radiology, Nuclear Medicine, Ultrasound, Cardiology and Documentation

Sign up to automatically receive our Q&As

Go to the Q&A webpage below at:
http://bracco.panaceainc.com/
Sign up today at:
http://bracco.panaceainc.com/bracco-qa-signup-form/

To get the most benefit from this service as a Bracco customer, we encourage you to:
- Bookmark the Q&A webpage to search for topics of interest Q&A on specific topics
- Sign up and receive the Q&A every two weeks

PLUS you will receive email invitations for accredited reimbursement webinars throughout the year!
REFERENCES


LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use INDICATIONS AND USAGE

LUMASON® is an ultrasound contrast agent indicated for use:

• in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult and pediatric patients with suboptimal echocardiograms
• in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients
• in ultrasonography of the urinary tract for the evaluation of suspected or known vesicoureteral reflux in pediatric patients

CONTRAINDICATIONS

LUMASON® is contraindicated in patients with:

• history of hypersensitivity reactions to sulfur hexafluoride lipid microsphere components or to any of the inactive ingredients in LUMASON®

IMPORTANT SAFETY INFORMATION

WARNING: SERIOUS CARDIOPULMONARY REACTIONS

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following the injection of ultrasound contrast agents, including sulfur hexafluoride lipid microspheres [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration [see Warnings and Precautions (5.1)].

• Assess all patients for the presence of any condition that precludes administration [see Contraindications (4)].
• Always have resuscitation equipment and trained personnel readily available [see Warnings and Precautions (5.1)].

The risk for serious cardiopulmonary reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, or serious ventricular arrhythmias) [see Warnings and Precautions (5.1)]. Hypersensitivity reactions have uncommonly been observed following the injection of Lumason [see Warnings and Precautions (5.2)]. The most common adverse reactions are headache and nausea [see Adverse Reactions (6.1)].¹

Please see full Prescribing Information for LUMASON ultrasound contrast agent including boxed WARNING at https://www.braccoimaging.com/us-en/products/contrast-enhanced-ultrasound/lumason

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/Safety/MedWatch/default.html or call 1-800-FDA-1088.

LUMASON is manufactured for Bracco Diagnostics Inc., Monroe Township, NJ 08831 by Bracco Suisse S.A., Plan-les-Ouates Geneve, Switzerland (LUMASON lyophilized powder vial-25 mg lipid-type A/60.7 sulfur hexafluoride gas); Vetter Pharma-Fertigung GmbH & Co. KG, 88212 Ravensburg, Germany (Sodium Chloride 0.9% Injection, USP); B. Braun Melsungen AG, 34212 Melsungen, Germany (Mini-Spike).

LUMASON is a registered trademark of Bracco Diagnostics Inc.